CPHI & PMEC India 2023 commenced on Tuesday at the India Expo Centre in Greater Noida, Delhi – NCR. The 16th edition provided a platform for stakeholders to participate in extensive dialogues covering pharma machinery, packaging, analytical instruments, laboratory technologies, equipment, ancillaries, ingredients, and beyond.
The 16th edition of CPHI & PMEC India builds on the success of the Pharma Leaders’ Golf and the CPHI Pre-Connect Congress just prior to the show. Themed “Integrate Innovation, Sustainability, and Growth,” this edition aimed to align and shape the roadmap for the next decade of Indian Pharma.
The signature trade expo brought together a vast assembly of industry experts, top manufacturers, the buyer’s community, policy advisors, and key stakeholders, uniting suppliers, innovators, and pharmaceutical leaders.
The grand inauguration ceremony was marked by the presence of key dignitaries Dr Veeramani S.V, Vice-Chairman PHARMEXCIL; Harish Jain, President FOPE; Raja Bhanu, Executive Director PHARMEXCIL, Margaret Ma, President & CEO – Informa Markets Asia; Chris Eve, Executive. Vice President – Informa Markets Asia; Adam Anderson, Executive Vice President – Pharma, Informa Markets; Yogesh Mudras, Managing Director, Informa Markets in India; Rahul Deshpande, Senior Group Director, Informa Markets in India, and Ranjith Paul, Group Director, Informa Markets in India.
“The Indian pharmaceutical industry is on a compelling growth trajectory, evidenced by an 8% year-to-date increase in exports and a remarkable 29% surge in October alone. This growth is propelled by expanding market opportunities, heightened demand in the USA, and critical shortages of medicines in the US and Europe. Despite challenges in CIS countries, the global reception of Indian pharmaceuticals remains positive. The domestic market has exhibited impressive growth, exceeding 10%. Driven by this momentum, I am confident in reaching the 130 billion mark by 2030, advocating for a consistent 10% growth in both domestic and export markets. Expos like CPHI & PMEC India are instrumental in propelling our industry forward, fostering innovation, and reinforcing India’s position on the global pharmaceutical stage,” Dr. Veeramani S.V., Chairman – Pharmexcil, said.
The current edition witnessed over 50,000 visitors and 1,500 exhibitors from over 80 countries, showcasing a diverse range of 10,000 products.
“While discussions revolve around India’s pharmaceutical landscape in 2030, our industry is visionary, setting its sights on India in 2047. Aligned with Prime Minister Narendra Modi’s concept of Amrit Kal, we anticipate a trajectory of sustained growth. Exceeding the projected $130 billion mark, the Department of Pharmaceuticals (DOP) envisions an ambitious $200 billion goal. Achieving this necessitates regulatory reforms to foster industry growth, address patient needs, and promote disruptive innovation, as we learned from the pandemic. Regarding the pharmaceutical sector’s outlook, we foresee stable double-digit growth, around 13-14%, conditional on consistent policies that streamline doing business. CPHI serves as a crucial platform to deliberate on achievements, challenges, and influence regulators for favourable business conditions,” Anil Matai, Director General, OPPI said.
Some of the notable exhibitors included Dr. Reddy’s Laboratories Ltd; Biocon Ltd; Glenmark Lifesciences Ltd; Piramal Pharma Solutions; Hetero Labs Limited; ACG; IMA Industria Macchine Automatiche S.P.A; Fette Compacting Machinery India Pvt. Ltd., Supriya Lifescience Ltd and Ace Technologies & Packaging Systems Pvt. Ltd. among others.
Moreover, the CPHI and PMEC India Expo is comprehensively supported by industry associations such as the Bulk Drug Manufacturing Association (BDMA), Federation of Pharma Entrepreneurs (FOPE), Karnataka Drugs and Pharmaceuticals Manufacturers’ Association (KDPMA), Organisation of Pharmaceutical Producers of India (OPPI), and PharmExcil.
Government-approved schemes in 2021 aim to develop substitute APIs, support global suppliers, and upgrade MSME sector standards to WHO-GIMP. This transformation aligns with the industry’s progress highlighted at CPHI and PMEC India 2023, where Mr. Eshwar Reddy, BDMA’s Executive Director, emphasized India’s robust performance in the 2023 CPHI Pharma Index, scoring 7.187. This underscores the industry’s drive for innovation and self-sufficiency, positioning these events as crucial platforms to showcase advancements, foster collaborations, and drive growth.”
“India’s pharmaceutical prowess, contributing a formidable 20% to global exports, achieved a remarkable USD 25.3 billion (INR 2.1 lakh crores) in the 2022–2023 fiscal year. Robust R&D investments from both domestic and international players drive innovation, a pivotal force propelling market expansion. With government backing, exemplified by Rs. 5,000 crores in R&D incentives, India emerges as a key leader in global healthcare development. The CPHI & PMEC India Expo, along with ancillary events during the India Pharma Week, stands as a premier global platform, fostering connections and collaborations within the pharmaceutical community. This year, hosting the largest-ever expo edition, it symbolizes India’s ascent as a monumental pharma superpower,” Yogesh Mudras, Managing Director, Informa Markets in India said.
As CPHI & PMEC India presents the latest technological advancements, the Pharma Leaders’ Roundtable emerged as a platform to explore innovations within the pharmaceutical sector. The focus of the talks was on charting a path for Indian pharmaceutical companies to attain global leadership by generating substantial value. Delving into crucial topics, the discussions centred around ‘Strengthening pharmaceutical innovation for broader reach, addressing unmet clinical needs, and embracing next-generation possibilities,’ as well as ‘Revolutionizing packaging, ensuring market access, and enhancing drug affordability.
Alongside, the India Pharma Awards celebrated excellence and innovation within the pharmaceutical space, acknowledging outstanding pharma brands for their noteworthy contributions to the industry. Day 2 witnessed the Women in Pharma Roundtable, which is an initiative aimed at acknowledging and celebrating the significant and continued contribution of women to the pharmaceutical industry in a closed-door roundtable discussion.
Over the next three days, this grand spectacle will keenly strive to shape the future landscape of the pharmaceutical industry through a seamless convergence of expertise from both the public and private sectors, as per the press statement.
